Analysis of clinical characteristics and factors affecting treatment responses in patients with pyoderma gangrenosum: a multicenter study of 239 patients

Comorbidity Hereditary autoinflammatory diseases Immunosuppressive agents Pyoderma gangrenosum Regression analysis

Journal

Anais brasileiros de dermatologia
ISSN: 1806-4841
Titre abrégé: An Bras Dermatol
Pays: Spain
ID NLM: 0067662

Informations de publication

Date de publication:
11 May 2024
Historique:
received: 30 10 2023
revised: 08 02 2024
accepted: 17 02 2024
medline: 13 5 2024
pubmed: 13 5 2024
entrez: 12 5 2024
Statut: aheadofprint

Résumé

Pyoderma Gangrenosum (PG) is a chronic disease characterized by recalcitrant skin ulcers. We aimed to evaluate the demographic, clinical characteristics, treatments and factors affecting the treatment responses of patients with PG. We performed a multicenter study of 12 tertiary care centers. We analyzed the data of the patients who were followed up with a diagnosis of PG between the years 2012‒2022 retrospectively. We included a total of 239 patients of whom 143 were female and 96 were male, with an average age of 54.2 ± 17.4 years. The most common treatment was systemic steroids (n = 181, 75.7%). Among these patients, 50.8% (n = 92) used systemic steroids as the sole systemic agent, while 49.2% (n = 89) used at least one adjuvant immunosuppressive agent. The independent factors determined in regression analysis to influence response to systemic steroids positively were disease onset age ≥ 30-years, negative pathergy, absence of leukocytosis, negative wound culture, presence of a single lesion, and absence of upper extremity involvement. Biological agents were used in 18.4% (n = 44) of the patients in the present study. We also analyzed pathergy positive PG and early onset (onset age < 30) PG separately due to their distinct clinical features which were revealed during statistical analysis. Retrospective nature of the present study. Analyses of the factors influencing treatment responses are addressed in this study. Also, we concluded that investigation for accompanying autoinflammatory diseases of pathergy positive PG and early onset PG is necessary and the patients in these two groups are more resistant to treatment, necessitating more complicated treatments.

Sections du résumé

BACKGROUND BACKGROUND
Pyoderma Gangrenosum (PG) is a chronic disease characterized by recalcitrant skin ulcers.
OBJECTIVE OBJECTIVE
We aimed to evaluate the demographic, clinical characteristics, treatments and factors affecting the treatment responses of patients with PG.
METHODS METHODS
We performed a multicenter study of 12 tertiary care centers. We analyzed the data of the patients who were followed up with a diagnosis of PG between the years 2012‒2022 retrospectively.
RESULTS RESULTS
We included a total of 239 patients of whom 143 were female and 96 were male, with an average age of 54.2 ± 17.4 years. The most common treatment was systemic steroids (n = 181, 75.7%). Among these patients, 50.8% (n = 92) used systemic steroids as the sole systemic agent, while 49.2% (n = 89) used at least one adjuvant immunosuppressive agent. The independent factors determined in regression analysis to influence response to systemic steroids positively were disease onset age ≥ 30-years, negative pathergy, absence of leukocytosis, negative wound culture, presence of a single lesion, and absence of upper extremity involvement. Biological agents were used in 18.4% (n = 44) of the patients in the present study. We also analyzed pathergy positive PG and early onset (onset age < 30) PG separately due to their distinct clinical features which were revealed during statistical analysis.
STUDY LIMITATIONS CONCLUSIONS
Retrospective nature of the present study.
CONCLUSIONS CONCLUSIONS
Analyses of the factors influencing treatment responses are addressed in this study. Also, we concluded that investigation for accompanying autoinflammatory diseases of pathergy positive PG and early onset PG is necessary and the patients in these two groups are more resistant to treatment, necessitating more complicated treatments.

Identifiants

pubmed: 38735817
pii: S0365-0596(24)00079-5
doi: 10.1016/j.abd.2024.02.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Funda Erduran (F)

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey. Electronic address: fnderdrn@gmail.com.

Esra Adışen (E)

Department of Dermatology, Gazi University Faculty of Medicine, Ankara, Turkey.

Yıldız Hayran (Y)

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey.

Güneş Gür Aksoy (GG)

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey.

Erkan Alpsoy (E)

Department of Dermatology, Akdeniz University Faculty of Medicine, Antalya, Turkey.

Leyla Baykal Selçuk (LB)

Department of Dermatology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.

Sibel Doğan Günaydın (SD)

Department of Dermatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Ayça Cordan Yazıcı (AC)

Department of Dermatology, Mersin University Faculty of Medicine, Mersin, Turkey.

Ayşe Öktem (A)

Ankara University Faculty of Medicine, Department of Dermatology, Ankara, Turkey.

Malik Güngör (M)

Department of Dermatology, Akdeniz University Faculty of Medicine, Antalya, Turkey.

Elif Afacan (E)

Department of Dermatology, Gazi University Faculty of Medicine, Ankara, Turkey.

Deniz Devrim Kuşçu (DD)

Ankara University Faculty of Medicine, Department of Dermatology, Ankara, Turkey.

Leyla Elmas (L)

Department of Dermatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Kübra Aydoğan (K)

Department of Dermatology, Mersin University Faculty of Medicine, Mersin, Turkey.

Dilek Bayramgürler (D)

Department of Dermatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.

Evren Odyakmaz Demirsoy (EO)

Department of Dermatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.

Melih Akyol (M)

Department of Dermatology, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Turkey.

Rukiye Yasak Güner (RY)

Department of Dermatology, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Turkey.

Hilal Kaya Erdoğan (HK)

Department of Dermatology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey.

Ersoy Acer (E)

Department of Dermatology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey.

Tulin Ergun (T)

Marmara University Faculty of Medicine, Department of Dermatology, İstanbul, Turkey.

Savaş Yaylı (S)

Department of Dermatology, Koç University Faculty of Medicine, İstanbul, Turkey.

Ferhan Bulut (F)

Marmara University Faculty of Medicine, Department of Dermatology, İstanbul, Turkey.

Esra Saraç (E)

Department of Dermatology, Koç University Faculty of Medicine, İstanbul, Turkey.

Akın Aktaş (A)

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey.

Classifications MeSH